|
|
|
|
|
|
|
11.11.26 - 16:18
|
3 Legacy Health Care Dividend Stocks That Never Go Out of Style (24/7 Wall St.)
|
|
|
Retirees who want income that keeps coming through recessions, rate swings and market scares often start with health care. People need heart devices, diagnostic tests and cancer drugs in every economy, and an aging population adds to that demand every year. Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) turn that steady demand […]...
|
|
|
|
|
03.11.26 - 13:33
|
BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026 (GlobeNewswire EN)
|
|
|
PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two moderated posters and three posters on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM), along with one BridgeBio-supported poster presentation led by Abbott Laboratories, will be shared at the American Heart Association (AHA) Scientific Sessions 2026, taking place in Chicago, Illinois on November 6-9, 2026. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.10.26 - 16:00
|
Abbott (ABT) Misses Q3 Earnings Estimates (Zacks)
|
|
|
Abbott (ABT) delivered earnings and revenue surprises of -0.70% and +0.30%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?...
|
|
|
21.10.26 - 14:42
|
Abbott will Ernährungsgeschäft abspalten (DPA-AFX)
|
|
|
ABBOTT PARK (dpa-AFX) - Der Pharmakonzern Abbott (Abbott Laboratories) will sein Ernährungsgeschäft in ein eigenständiges und börsennotiertes Unternehmen ausgliedern. Die Abspaltung solle bis Ende 2027 abgeschlossen ......
|
|
|
|
|
|
|
|